Neuronetics, Inc. (STIM) — SEC Filings
Neuronetics, Inc. (STIM) — 50 SEC filings. Latest: 10-Q (May 5, 2026). Includes 26 8-K, 7 10-Q, 6 SC 13G/A.
View Neuronetics, Inc. on SEC EDGAR
Overview
Neuronetics, Inc. (STIM) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 8-K filed on Nov 4, 2025: Neuronetics, Inc. filed an 8-K on November 4, 2025, reporting on its results of operations and financial condition. The filing also covers the departure of directors or certain officers, election of directors, appointment of certain officers, and compensatory arrangements. Additionally, it includes
Sentiment Summary
Across 50 filings, the sentiment breakdown is: 1 bullish, 2 bearish, 45 neutral, 2 mixed. The dominant filing sentiment for Neuronetics, Inc. is neutral.
Filing Type Overview
Neuronetics, Inc. (STIM) has filed 7 10-Q, 26 8-K, 1 EFFECT, 2 DEF 14A, 2 10-K, 2 8-K/A, 1 SC 13D, 6 SC 13G/A, 1 DEFA14A, 2 SC 13G with the SEC between Jan 2024 to May 2026.
Filings by Year
Recent SEC Filings (50)
Risk Profile
Risk Assessment: Of STIM's 35 recent filings, 0 were flagged as high-risk, 16 as medium-risk, and 19 as low-risk. The overall risk profile suggests relatively low risk with generally favorable filings.
Financial Highlights
| Metric | Value |
|---|---|
| Revenue | $107.4M |
| Net Income | ($31.9M) |
| EPS | N/A |
| Debt-to-Equity | 4.36 |
| Cash Position | $27.97M |
| Operating Margin | N/A |
| Total Assets | $145.47M |
| Total Debt | $65.67M |
Key Executives
- Todd L. Carpenter
- Brian J. Baker
- Dr. David M. Bear
- Mr. David M. D. Smith
- Dr. David M. D. Smith
- Mr. David L. Johnson
- Dr. Christopher R. White
- Michael R. Rago
- Mark D. Johnson
- Dr. David L. R. Smith
- Ms. Jennifer L. Chien
Industry Context
Neuronetics operates in the medical device sector, specifically focusing on neurohealth solutions. The industry is characterized by high R&D costs, stringent regulatory hurdles (FDA approval), and evolving reimbursement landscapes. Competition can come from established medical device companies and emerging players offering alternative therapies. The recent acquisition of Greenbrook TMS Inc. suggests a strategy to consolidate market share and expand service offerings within the neurohealth space.
Top Tags
8-K (7) · financials (4) · Medical Devices (3) · corporate-governance (3) · 10-Q (3) · governance (3) · medical-devices (3) · material-agreement (3) · amendment (3) · financial-reporting (3)
Key Numbers
| Metric | Value | Context |
|---|---|---|
| Q3 2025 Revenue | $37.3M | Increased from $18.5M in Q3 2024, a 101.6% increase |
| YTD 2025 Revenue | $107.4M | Increased from $52.4M in YTD 2024, a 105% increase |
| Q3 2025 Net Loss | ($9.4M) | Improved from ($13.3M) in Q3 2024, a 29.4% reduction |
| YTD 2025 Net Loss | ($31.9M) | Slightly worsened from ($31.0M) in YTD 2024, a 2.9% increase |
| Accumulated Deficit | $451.6M | As of September 30, 2025, indicating historical losses |
| YTD 2025 Operating Cash Flow | ($21.3M) | Improved from ($22.4M) in YTD 2024, a 4.9% improvement |
| Net Proceeds from Secondary Offering | $18.9M | Received in February 2025 to boost liquidity |
| Net Proceeds from ATM Program | $7.8M | Received by September 30, 2025, from selling 2,261,835 shares |
| Long-term Debt Outstanding | $70.0M | As of September 30, 2025, maturing in July 2029 |
| Common Shares Outstanding | 68,485,922 | As of October 29, 2025 |
| Q2 2025 Revenue | $66.11M | Increased from $55.68M in Q2 2024, showing 18.7% growth. |
| Revenue Growth | 18.7% | Percentage increase in revenue from Q2 2024 to Q2 2025. |
| At-Market Equity Offering Program Date | 2025-08-05 | Indicates a new capital raising strategy. |
| Shares for 2020 Incentive Plan | 1,000,000 | Authorized shares as of December 9, 2024, impacting potential dilution. |
| Shares for 2018 Incentive Plan | 1,500,000 | Authorized shares as of December 9, 2024, impacting potential dilution. |
Related Companies
Frequently Asked Questions
What are the latest SEC filings for Neuronetics, Inc. (STIM)?
Neuronetics, Inc. has 50 recent SEC filings from Jan 2024 to May 2026, including 26 8-K, 7 10-Q, 6 SC 13G/A. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of STIM filings?
Across 50 filings, the sentiment breakdown is: 1 bullish, 2 bearish, 45 neutral, 2 mixed. The dominant sentiment is neutral.
Where can I find Neuronetics, Inc. SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Neuronetics, Inc. (STIM) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Neuronetics, Inc.?
Key financial highlights from Neuronetics, Inc.'s most recent 10-Q include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.
What is the investment thesis for STIM?
The investment thesis for STIM includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.
Who are the key executives at Neuronetics, Inc.?
Key executives identified across Neuronetics, Inc.'s filings include Todd L. Carpenter, Brian J. Baker, Dr. David M. Bear, Mr. David M. D. Smith, Dr. David M. D. Smith and 6 others.
What are the main risk factors for Neuronetics, Inc. stock?
Of STIM's 35 assessed filings, 0 were flagged high-risk, 16 medium-risk, and 19 low-risk.
What are recent predictions and forward guidance from Neuronetics, Inc.?
Forward guidance and predictions for Neuronetics, Inc. are extracted from SEC filings as they are enriched.